How to Control Impurities during API drug manufacturing

Posted: February 19, 2018

Author:
Tags: API Manufacturing | Impurities | Video
API Manufacturing and Pharmaceutical Manufacturing

Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.

Related posts:

Controlling Impurities In Drug Manufacturing
Best practices in following ICH guidelines for APIs
When Raw Materials Don’t Meet Specs
Setting Comprehensive Specifications in API Manufacturing
Top Analytical Method Validation Mistakes and How to Avoid Them – Part 2

About the Author

Ed Price CEO of PCI Synthesis
Ed is the President and CEO of PCI Synthesis (PCI), he serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA).

Do you have questions? Talk to Ed.